|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carrato A, Gallego-Plazas J and
Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is
necessary. Semin Oncol. 32(6 Suppl 9): S105–S108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kalow W, Tang BK and Endrenyi L:
Hypothesis: comparisons of inter- and intra-individual variations
can substitute for twin studies in drug research. Pharmacogenetics.
8:283–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adleff V, Hitre E, Köves L, Orosz Z,
Hajnal A and Kralovánszky J: Heterozygote deficiency in thymidylate
synthase enhancer region polymorphism genotype distribution in
Hungarian colorectal cancer patients. Int J Cancer. 108:852–856.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graziano F, Kawakami K, Watanabe G, Ruzzo
A, Humar B, Santini D, Catalano V, Ficarelli R, Merriman T, Panunzi
S, et al: Association of thymidylate synthase polymorphisms with
gastric cancer susceptibility. Int J Cancer. 112:1010–1014. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mandola MV, Stoehlmaeher J, Zhang W,
Groshen S, Yu MC, Iqbal S, Lenz HJ and Ladner RD: A 6 bp
polymorphism in the thymidylate synthase gene causes message
instability and is associated with decreased intratumoral TS mRNA
levels. Pharmacogeneties. 14:319–327. 2004. View Article : Google Scholar
|
|
7
|
Chen J, Hunter DJ, Stampfer MJ, Kyte C,
Chan W, Wetmur JG, Mosig R, Selhub J and Ma J: Polymorphism in the
thymidylate synthase promoter enhancer region modifies the risk and
survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev.
12:958–962. 2003.PubMed/NCBI
|
|
8
|
Cascinu S, Aschele C, Barni S, Debernardis
D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P
and Catalano G: Thymidylate synthase protein expression in advanced
colon cancer: correlation with the site of metastasis and the
clinical response to leucovorin-modulated bolus 5-fluorouracil.
Clin Cancer Res. 5:1996–1999. 1999.PubMed/NCBI
|
|
9
|
Davies MM, Johnston PG, Kaur S and
Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase
staining correlates with response to hepatic arterial floxuridine.
Clin Cancer Res. 5:325–328. 1999.PubMed/NCBI
|
|
10
|
Raymond E, Faivre S, Woynarowski JM and
Chaney SG: Oxaliplatin: mechanism of action and antineoplastic
activity. Semin Oncol. 25(2 Suppl 5): S4–S12. 1998.
|
|
11
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing group 1: gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
12
|
Yin M, Yan J, Martinez-Balibrea E,
Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS,
Etienne-Grimaldi MC and Wei Q: ERCC1 and ERCC2 polymorphisms
predict clinical outcomes of oxaliplatin-based chemotherapies in
gastric and colorectal cancer: a systemic review and meta-analysis.
Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin M, Yan J, Martinez-Balibrea E,
Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS,
Etienne-Grimaldi MC and Wei Q: ERCC1 and ERCC2 polymorphisms
predict clinical outcomes of oxaliplatin-based chemotherapies in
gastric and colorectal cancer: A systemic review and meta-analysis.
Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brody JR, Hucl T, Gallmeier E, Winter JM,
Kern SE and Murphy KM: Genomic copy number changes affecting the
thymidylate synthase (TYMS) gene in cancer: a model for patient
classification to aid fluoropyrimidine therapy. Cancer Res.
66:9369–9373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watson RG, Muhale F, Thorne LB, Yu J,
O'Neil BH, Hoskins JM, Meyers MO, Deal AM, Ibrahim JG, Hudson ML,
et al: Amplification of thymidylate synthetase in metastatic
colorectal cancer patients pretreated with 5-fluorouracil-based
chemotherapy. Eur J Cancer. 46:3358–3364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morganti M, Ciantelli M, Giglioni B,
Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R,
Cianchi F, et al: Relationships between promoter polymorphisms in
the thymidylate synthase gene and mRNA levels in colorectal
cancers. Eur J Cancer. 41:2176–2183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yawata A, Kim SR, Miyajima A, Kubo T,
Ishida S, Saito Y, Nakajima Y, Katori N, Matsumoto Y, Fukuoka M, et
al: Polymorphic tandem repeat sequences of the thymidylate synthase
gene correlates with cellular-based sensitivity to fluoropyrimidine
antitumor agents. Cancer Chemother Pharmacol. 56:465–472. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang ZH, Hua D and Li LH: The
polymorphisms of TS and MTHFR predict survival of gastric cancer
patients treated with fluorouracil-based adjuvant chemotherapy in
Chinese population. Cancer Chemother Pharmacol. 63:911–918. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cui YH, Liu TS, Zhuang RY, Gao HJ and Li
H: Polymorphism of thymidylate synthase gene and chemosensitivity
of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J
Dig Dis. 10:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Villafranca E, Okruzhnov Y, Dominguez MA,
García-Foncillas J, Azinovic I, Martínez E, Illarramendi JJ, Arias
F, Martínez Monge R, Salgado E, et al: Polymorphisms of the
repeated sequences in the enhancer region of the thymidylate
synthase gene promoter may predict downstaging after preoperative
chemoradiation in rectal cancer. J Clin Oncol. 19:1779–1786.
2001.PubMed/NCBI
|
|
21
|
Pullarkat ST, Stoehlmacher J, Ghaderi V,
Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S and
Lenz HJ: Thymidylate synthase gene polymorphism determines response
and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1:65–70.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marsh S, McKay JA, Cassidy J and McLeod
HL: Polymorphism in the thymidylate synthase promoter enhancer
region in colorectal cancer. Int J Oncol. 19:383–386.
2001.PubMed/NCBI
|
|
23
|
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei
D, Groshen S and Lenz HJ: Thymidylate synthasegene polymorphism
predicts response to capecitabine in advanced colorectal cancer.
Int J Colorectal Dis. 17:46–49. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matasui T, Omura K, Kawakami K, Morita S
and Sakamoto J: Genotype of thymidylate synthase likely to affect
efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol
Rep. 16:1111–1115. 2006.PubMed/NCBI
|
|
25
|
Kakimoto M, Uetake H, Osanai T, Shirota Y,
Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV and
Sugihara K: Thymidylate synthase and dihydropyrimidine
dehydrogenase gene expression in breast cancer predicts 5-FU
sensitivity by a histocultural drug sensitivity test. Cancer Lett.
223:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ulrich CM, Bigler J, Velicer CM, Greene
EA, Farin FM and Potter JD: Searching expressed sequence tag
databases: discovery and confirmation of a common polymorphism in
the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev.
9:1381–1385. 2000.PubMed/NCBI
|
|
27
|
Mandola MV, Stoehlmacher J, Muller-Weeks
S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: A novel single
nucleotide polymorphism within the 5′ tandem repeat polymorphism of
the thymidylate synthase gene abolishes USF1 binding and alters
transcriptional activity. Cancer Res. 63:2898–2904. 2003.PubMed/NCBI
|
|
28
|
Ulrich CM, Bigler J, Bostick R, Fosdick L
and Potter JD: Thymidylate synthase promoter polymorphism
interaction with folate intake and risk of colorectal adenomas.
Cancer Res. 62:3361–3364. 2002.PubMed/NCBI
|
|
29
|
Won DY, Kim SH, Hur H, Jung H and Jeon HM:
Chemotherapeutic responsibility according to polymorphism of ERCC1,
XRCC1 and GSPT1 in gastric cancer patients receiving oxaliplatin
based chemotherapy. J Korean Surg Soc. 8:350–356. 2010. View Article : Google Scholar
|
|
30
|
Liu YP, Ling Y, Zhang YP and Liu BR:
Predictive values of platinum related gene polymorphisms in gastric
cancer patients on oxaliplatin-based adjuvant chemotherapy.
Zhonghua Yi Xue Za Zhi. 91:256–259. 2011.(In Chinese). PubMed/NCBI
|
|
31
|
Ruzzo A, Graziano F, Kawakami K, Watanabe
G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R,
Menichetti ET, et al: Pharmacogenetic profiling and clinical
outcome of patients with advanced gastric cancer treated with
palliative chemotherapy. J Clin Oncol. 24:1883–1891. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ruzzo A, Graziano F, Loupakis F, Rulli E,
Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P,
Bisonni R, et al: Pharmacogenetic profiling in patients with
advanced colorectal cancer treated with first-line FOLFOX-4
chemotherapy. J Clin Oncol. 25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Viguier J, Boige V, Miquel C, Pocard M,
Giraudeau B, Sabourin JC, Ducreux M, Sarasin A and Praz F: ERCC1
codon 118 polymorphism is a predictive factor for the tumor
response to oxaliplatin/5-fluorouracil combination chemotherapy in
patients with advanced colorectal cancer. Clin Cancer Res.
11:6212–6217. 2005. View Article : Google Scholar : PubMed/NCBI
|
